Changes in Hong Kong stocks | Peger Biopharmaceutical-B (02565) rose by nearly 5% and is expected to accelerate its volume after successful inclusion in national health insurance

Zhitongcaijing · 1d ago

The Zhitong Finance App learned that Peger Biopharmaceutical-B (02565) increased by nearly 5%. As of press release, it rose 3.57% to HK$3.335, with a turnover of HK$21.5625 million.

According to the news, Peger Biotech's core product, Paidacan® (vipernatide injection), was successfully included in the 2026 national medical insurance drug catalogue, and commercialization ushered in significant progress. Earlier, Peger and Shanghai Tengrui Pharmaceuticals reached an exclusive commercial cooperation in mainland China, setting the goal of cumulative sales exceeding RMB 10 billion. , Product sales revenue is recognized by Peger.

According to public information, Pidacan is a GLP-1 weekly preparation for blood sugar control in adults with type 2 diabetes. The company said that Paidacang is the Group's first innovative pharmaceutical product approved for marketing. The inclusion in the national medical insurance catalogue is expected to improve the patient affordability and drug accessibility of the product, which is conducive to promoting the entry, clinical promotion and market coverage of the product in medical institutions across the country.